Search Results

FastPack® IP SHBG is a chemiluminescent immunoassay intended for the quantitative determination of Sex Hormone Binding Globulin in human serum and plasma on the FastPack® System. The FastPack® IP SHBG assay is intended for use as an aid in the diagnosis of androgen disorders.

The FastPack® IP Sex Hormone Binding Globulin Immunoassay employs a sandwich immunoassay principle. Endogenous SHBG in a patient sample, calibrator, or control is dispensed into a FastPack® reagent pack. In the reagent pack, the sample binds with a monoclonal anti-SHBG antibody covalently linked to alkaline phosphatase (ALP) and a different monoclonal anti-SHBG antibody linked to biotin will bind to streptavidin coated paramagnetic particles (PMP). After incubation, washing steps (using a Tris buffer containing detergents) occur to separate bound from unbound anti-SHBG monoclonal antibody-ALP, a chemiluminogenic substrate mixture is added to the system. This mixture contains indoxyl-3-phosphate, a substrate for ALP, and lucigenin (N,N dimethyl-9,9'-biacridinium dinitrate). ALP dephosphorylates indoxyl-3-phosphate to indol-3-ol, which subsequently undergoes oxidation. As a result, lucigenin is reduced to form a dioxetane structure that is cleaved to yield N-methylacridone. This compound produces a sustained luminescent glow following excitation. The raw relative luminescence units (RLUs) generated are measured by a photomultiplier tube in the FastPack® Analyzer and are directly proportional to the concentration of SHBG in the sample. The entire reaction sequence takes place at 37 ± 0.5 ℃ and is protected from external light.

Here's an analysis of the provided text regarding the FastPack® IP Sex Hormone Binding Globulin Immunoassay's acceptance criteria and studies:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state formal "acceptance criteria" for all performance characteristics in a separate section. However, based on the comparative effectiveness study against a predicate device and the presented performance data, we can infer some implied acceptance ranges or targets for the new device.

2. Sample Size and Data Provenance for Test Set (Performance Studies)

• Precision: 7 serum patient samples, tested in duplicate over 20 non-consecutive days, resulting in 240 replicate determinations per sample.
• LOB/LOD: 180 replicate determinations of a blank sample (LOB) and 180 replicate determinations of four low-level samples (LOD).
• Linearity: 11 concentration levels generated by intermixing high and low patient samples, each tested in quadruplicate.
• Interferences: Two serum samples (low and high SHBG concentrations) spiked with known interfering concentrations.
• Serum and Plasma Equivalence: Blood collections from 54 volunteers.
• Expected Values/Reference Intervals: N=613 male (n=304) and female (n=309) apparently healthy individuals.
• Method Comparison: 158 human serum samples.

Data Provenance (Implied): The studies refer to "patient samples," "serum samples," and "human serum/plasma." While direct country of origin is not specified, it's generally understood that such studies for FDA submission are conducted under controlled laboratory conditions, likely within the US or by institutions adhering to similar regulatory standards. The data is retrospective in the sense that these are collected samples used for performance evaluation, not part of real-time clinical use for new diagnoses in a prospective clinical trial.

3. Number of Experts and Qualifications for Ground Truth

This device is an in vitro diagnostic (IVD) immunoassay that measures a biomarker (SHBG concentration). The concept of "ground truth" here is the true concentration of SHBG in a sample, or the accuracy of the measurement against a reference method.

• No human experts (like radiologists reading images) are used to establish ground truth for individual measurements of SHBG concentration.
• For Method Comparison: The "ground truth" or reference standard for comparison is the predicate device (Beckman Coulter Access Sex Hormone Binding Globulin assay K083867). This predicate device itself had previously established performance.
• For Reference Intervals (Expected Values): "Apparently healthy individuals with no known pre-existing endocrine disorders" were used. The reference intervals (2.5th-97.5th percentiles) are derived statistically from a population, rather than established by individual expert diagnosis for each sample.

4. Adjudication Method for the Test Set

Not applicable. As described above, the "ground truth" for this IVD is either the measurement by a predicate device or statistically derived normal ranges, not expert interpretation requiring adjudication.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

Not applicable. This is an automated immunoassay for quantitative determination of a biomarker, not an imaging device or AI algorithm that assists human readers in interpreting cases. There is no "human-in-the-loop" component in the direct measurement process to be evaluated for improvement with AI assistance.

6. Standalone (Algorithm Only) Performance

Yes, the studies presented are all standalone performance evaluations of the FastPack® IP Sex Hormone Binding Globulin Immunoassay system (device + assay + analyzer). The device operates independently to provide quantitative results.

7. Type of Ground Truth Used

• For Method Comparison: The measurements from the predicate device (Beckman Coulter Access Sex Hormone Binding Globulin assay) served as the comparative "truth" or reference.
• For Limit of Quantitation (LOQ): Defined by statistical criteria (lowest concentration with < 20% CV).
• For Linearity: Based on spiked samples with known concentrations and statistical fit to a linear model.
• For Interfering Substances/Cross-reactivity: Based on known spiked concentrations of potential interferents and lack of significant deviation from unspiked controls.
• For Expected Values/Reference Intervals: Statistically derived from a large population of apparently healthy individuals.
• Traceability: The assay is traceable to WHO 082/266 reference material, which serves as a primary reference for SHBG concentration.

8. Sample Size for the Training Set

Not applicable in the typical AI/ML sense. This is a conventional in vitro diagnostic device, not an AI/ML system that requires a "training set" to learn from data. The device's performance characteristics are established through analytical validation studies (precision, linearity, interference, method comparison, etc.) as described. The calibration curve for the assay is established using known calibrator materials, but this is part of the daily operational setup, not a "training set" in the context of AI.

9. How the Ground Truth for the Training Set Was Established

Not applicable for the same reasons as #8. The assay relies on known concentrations of calibrators (traceable to WHO reference material) to establish its quantitative scale, not on a "ground truth" established for an AI training set.

Ask a specific question about this device